These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 29719977)

  • 1. Regulatory/Scientific Supports for Micro-, Small-, and Medium-Sized Enterprises (SMEs) With Medicinal Products Provided by the PMDA and EMA.
    Kondo H; Shibatsuji M; Yasuda N
    Ther Innov Regul Sci; 2019 Mar; 53(2):193-198. PubMed ID: 29719977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Small- and Medium-sized Enterprises Office (SME Office) at the European Medicines Agency.
    Carr M
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):20-3. PubMed ID: 20101799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What to Know About Medicines With New Active Ingredients Approved in FY 2016 / 2016 in Japan and EU: A Brief Comparison of New Medicines Approved in Japan and the EU in 2016.
    Kondo H; Saint-Raymond A; Yasuda N
    Ther Innov Regul Sci; 2018 Mar; 52(2):214-219. PubMed ID: 29714521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulatory structures for gene therapy medicinal products in the European Union.
    Klug B; Celis P; Carr M; Reinhardt J
    Methods Enzymol; 2012; 507():337-54. PubMed ID: 22365782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Comparison of PMDA and EMA Consultations for Regulatory and Scientific Matters in Drugs and Regenerative Medicine Products.
    Kondo H; Sugita T; Ida N; Fukushima H; Yasuda N
    Ther Innov Regul Sci; 2017 May; 51(3):355-359. PubMed ID: 30231707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Flexible and Expedited Regulatory Review Processes for Innovative Medicines and Regenerative Medical Products in the US, the EU, and Japan.
    Nagai S
    Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31382625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The certification of advanced therapy medicinal products. A quality label for product development in small and medium-sized enterprises].
    Berger A; Schüle S; Flory E
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):816-21. PubMed ID: 21698534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Marketing authorisation applications submitted to the European Medicines Agency by small and medium-sized enterprises: an analysis of major objections and their impact on outcomes.
    Amaouche N; Casaert Salomé H; Collignon O; Santos MR; Ziogas C
    Drug Discov Today; 2018 Oct; 23(10):1801-1805. PubMed ID: 29953957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship Between the Review Time and Various PMDA Consultations in Recent New Drug Approval Cases in Japan.
    Nishiyama K; Toyoshima S; Yamada H; Suzuki H; Nagai N
    Ther Innov Regul Sci; 2018 Nov; 52(6):731-738. PubMed ID: 29714577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Scientific advice by the national and European approval authorities concerning advanced therapy medicinal products].
    Jost N; Schüssler-Lenz M; Ziegele B; Reinhardt J
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Nov; 58(11-12):1207-14. PubMed ID: 26369763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmaceuticals Licensing and Reimbursement in the European Union, United States, and Japan.
    Oye KA; Eichler HG; Hoos A; Mori Y; Mullin TM; Pearson M
    Clin Pharmacol Ther; 2016 Dec; 100(6):626-632. PubMed ID: 27618128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Report from the Committee for Advanced Therapies (CAT). Pitfalls on the way from concept to medical treatment with advanced therapy medicinal products].
    Reiss M; Büttel IC; Schneider CK
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):822-30. PubMed ID: 21698535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Regulatory authorities expect innovative drug delivery systems (DDS)].
    Mori K
    Yakugaku Zasshi; 2013; 133(1):73-80. PubMed ID: 23292023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Current Status of Sakigake Designation in Japan, PRIME in the European Union, and Breakthrough Therapy Designation in the United States.
    Kondo H; Hata T; Ito K; Koike H; Kono N
    Ther Innov Regul Sci; 2017 Jan; 51(1):51-54. PubMed ID: 30235998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Engaging with economic evaluation methods: insights from small and medium enterprises in the UK medical devices industry after training workshops.
    Craven MP; Allsop MJ; Morgan SP; Martin JL
    Health Res Policy Syst; 2012 Sep; 10():29. PubMed ID: 22943625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmaceuticals and Medical Devices Agency (PMDA)'s new action for Pharmaceutical Affairs Consultation on Research and Development (R&D) Strategy].
    Masuyama K
    Yakugaku Zasshi; 2013; 133(2):183-6. PubMed ID: 23370511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Barriers to Creating Scalable Business Models for Digital Health Innovation in Public Systems: Qualitative Case Study.
    Kelley LT; Fujioka J; Liang K; Cooper M; Jamieson T; Desveaux L
    JMIR Public Health Surveill; 2020 Dec; 6(4):e20579. PubMed ID: 33300882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. From molecule to market access: drug regulatory science as an upcoming discipline.
    Gispen-de Wied CC; Leufkens HGM
    Eur J Pharmacol; 2013 Nov; 719(1-3):9-15. PubMed ID: 23891846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
    Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
    Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The use of nanotechnology in medicinal products in the light of European Union law].
    Jurewicz M
    Pol Merkur Lekarski; 2014 Dec; 37(222):369-72. PubMed ID: 25715580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.